EVEREST MEDICINES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.35 HKD | -4.11% |
|
-10.36% | +11.72% |
| 05-14 | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
| 05-14 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 959M | - | |||||
| 90.45B | ||||||
| 41.45B | ||||||
| 33.57B | ||||||
| 25.73B | ||||||
| 14.73B |
